cobas® eplex BCID Panel 94.3% 93.6% 97.8% 94.6% Competitor 1 BCID 84.3% 86.6% 89.6% 85.3% Competitor 1 BCID v2 86.8% 89.1% 90.4% 86.4% Competitor 2 BC 83.1% 83.0% 85.5% 83.5% Competitor 3 BC ID 78.1% 82.1% 85.9% 73.3% Table 1: Blood culture panel target inclusivity based on ...
The GenMark Dx ePlex BCID Gram-Negative (GN) panel utilizes electrowetting technology to detect the most common causes of GN bacteremia (21 targets) and 6 antimicrobial resistance (AMR) genes from positive blood culture (BC) bottles. Rapid detection of extended spectrum 尾-lactamases (ESBL: CTX...
The cobas eplex blood culture identification panels (BCID) are multiplexed nucleic acid tests for the qualitative detection of ~95% of the organisms that can cause bloodstream infections which can lead to sepsis. This is the broadest coverage of gram-positive, gra...
The EUA-authorized and CE-Marked ePlex RP2 Panel runs on GenMark’s ePlex instrument, which is FDA cleared and CE-Marked for use with the company’s ePlex RP Panel and Blood Culture Identification (BCID) Panels (Gram-positive, Gram-negati...
The ePlex BCID Gram-Positive (GP) panel utilizes electrowetting technology to detect the most common causes of GP bacteremia (20 targets) and 4 antimicrobial resistance genes in positive blood culture bottles. Rapid detection of intrinsic vancomycin resistance and acquired resistance genes (mecA, mecC...
1022. Evaluating the Impact of GenMark Dx ePlex Blood Culture Identification (BCID) on Gram-negative Bloodstream InfectionsPia Cumagun, MDJeremy Meeder, BSDerek Moates, BS, MSHannah Pierce, BS, MSTodd P McCarty, MDRachael A Lee, MDSixto M Leal, Jr., MD, PhD...
A comparison with the competing kits is provided.Expert commentaries: The ePlex BCID-FP test provides a diversified and rather relevant panel. Its easy-to-use cartridges allow flexible use around the clock. Nevertheless, prospective clinical studies assessing the time-to-result benefit on antifungal ...
Implementation of the GenMark ePlex BCID-GP panel reduced time to targeted antibiotic therapy by nearly 24 hours. Clinical outcomes including hospital LOS and all-cause 30-day mortality did not show a statistical difference, although analysis of a larger sample size is necessary to appropriately ...